Prolonged first‐line PEG‐asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol—Pharmacokinetics and antibody formation

Abstract

We conclude that prolonged first-line biweekly PEG-asparaginase therapy, 1,000 IU/m²/dose was above the pharmacological target in the vast majority of patients. Presence of anti-PEG-asparaginase antibodies was not a predictor of l-asparaginase activity.